Displaying publications 1 - 20 of 76 in total

Abstract:
Sort:
  1. Aziz A, Agamuthu P, Fauziah SH
    Waste Manag Res, 2018 Oct;36(10):975-984.
    PMID: 30058954 DOI: 10.1177/0734242X18790360
    Landfill leachate contain persistent organic pollutants (POPs), namely, bisphenol A (BPA) and 2,4-Di-tert-butylphenol, which exceed the permissible limits. Thus, such landfill leachate must be treated before it is released into natural water courses. This article reports on investigations about the removal efficiency of POPs such as BPA and 2,4-Di-tert-butylphenol from leachate using locust bean gum (LBG) in comparison with alum. The vital experimental variables (pH, coagulant dosage and stirring speed) were optimised by applying response surface methodology equipped with the Box-Behnken design to reduce the POPs from leachate. An empirical quadratic polynomial model could accurately model the surface response with R2 values of 0.928 and 0.954 to reduce BPA and 2,4-Di-tert-butylphenol, respectively. Fourier transform infrared (FTIR) spectroscopy and scanning electron microscopy (SEM) were performed on treated flocs for further understanding. FTIR analysis revealed that the bridging of pollutant particles could be due to the explicit adsorption and bridging via hydrogen bonding of a coagulation mechanism. SEM micrographs indicated that the flocs produced by LBG have a rough cloudy surface and numerous micro-pores compared with alum, which enabled the capture and removal of POPs from leachate. Results showed that the reduction efficiencies for BPA and 2,4-Di-tert-butylphenol at pH 7.5 were 76% and 84% at LBG dosage of 500 mg·L-1 and 400 mg·L-1, respectively. Coagulant dosage and pH variation have a significant effect on POPs reduction in leachate. Coagulation/flocculation using LBG could be applied for POPs reduction in leachate as a pre-treatment prior to advanced treatments.
    Matched MeSH terms: Benzhydryl Compounds
  2. Tan BL, Kassim NM, Mohd MA
    Toxicol Lett, 2003 Aug 28;143(3):261-70.
    PMID: 12849686
    The effects of bisphenol A and nonylphenol on pubertal development in the intact juvenile/peripubertal male Sprague-Dawley rats was observed in this study from PND23-52/53. Two groups of rats were administered orally with either 100 mg/kg body weight of nonylphenol or bisphenol A. Another group of rats were administered orally with a mixture of 100 mg/kg body weight of nonylphenol and bisphenol A. Control group was administered with the vehicle of Tween-80 with corn oil (1:9 v/v). Observations made in this study included growth, age at preputial separation, thyroid, liver, testis and kidney weight and histology, epididymal and seminal vesicle plus coagulation gland weight. Nonylphenol and bisphenol A have been observed to cause delay in puberty onset as well as testicular damage in the treatment groups when compared to the control; spermatogenesis was affected in most treated rats. Bisphenol A also caused the enlargement of the kidney and hydronephrosis. Administration of nonylphenol and bisphenol A as a mixture has caused less than additive effects.
    Matched MeSH terms: Benzhydryl Compounds
  3. Cherney DZI, Dekkers CCJ, Barbour SJ, Cattran D, Abdul Gafor AH, Greasley PJ, et al.
    Lancet Diabetes Endocrinol, 2020 07;8(7):582-593.
    PMID: 32559474 DOI: 10.1016/S2213-8587(20)30162-5
    BACKGROUND: SGLT2 inhibition decreases albuminuria and reduces the risk of kidney disease progression in patients with type 2 diabetes. These benefits are unlikely to be mediated by improvements in glycaemic control alone. Therefore, we aimed to examine the kidney effects of the SGLT2 inhibitor dapagliflozin in patients with proteinuric kidney disease without diabetes.

    METHODS: DIAMOND was a randomised, double-blind, placebo-controlled crossover trial done at six hospitals in Canada, Malaysia, and the Netherlands. Eligible participants were adult patients (aged 18-75 years) with chronic kidney disease, without a diagnosis of diabetes, with a 24-h urinary protein excretion greater than 500 mg and less than or equal to 3500 mg and an estimated glomerular filtration rate (eGFR) of at least 25 mL/min per 1·73 m2, and who were on stable renin-angiotensin system blockade. Participants were randomly assigned (1:1) to receive placebo and then dapagliflozin 10 mg per day or vice versa. Each treatment period lasted 6 weeks with a 6-week washout period in between. Participants, investigators, and study personnel were masked to assignment throughout the trial and analysis. The primary outcome was percentage change from baseline in 24-h proteinuria during dapagliflozin treatment relative to placebo. Secondary outcomes were changes in measured GFR (mGFR; via iohexol clearance), bodyweight, blood pressure, and concentrations of neurohormonal biomarkers. Analyses were done in accordance with the intention-to-treat principle. This study is registered with ClinicalTrials.gov, NCT03190694.

    FINDINGS: Between Nov 22, 2017, and April 5, 2019, 58 patients were screened, of whom 53 (mean age 51 years [SD 13]; 32% women) were randomly assigned (27 received dapagliflozin then placebo and 26 received placebo then dapagliflozin). One patient discontinued during the first treatment period. All patients were included in the analysis. Mean baseline mGFR was 58·3 mL/min per 1·73 m2 (SD 23), median proteinuria was 1110 mg per 24 h (IQR 730-1560), and mean HbA1c was 5·6% (SD 0·4). The difference in mean proteinuria change from baseline between dapagliflozin and placebo was 0·9% (95% CI -16·6 to 22·1; p=0·93). Compared with placebo, mGFR was changed with dapagliflozin treatment by -6·6 mL/min per 1·73 m2 (-9·0 to -4·2; p<0·0001) at week 6. This reduction was fully reversible within 6 weeks after dapagliflozin discontinuation. Compared with placebo, bodyweight was reduced by 1·5 kg (0·03-3·0; p=0·046) with dapagliflozin; changes in systolic and diastolic blood pressure and concentrations of neurohormonal biomarkers did not differ significantly between dapagliflozin and placebo treatment. The numbers of patients who had one or more adverse events during dapagliflozin treatment (17 [32%] of 53) and during placebo treatment (13 [25%] of 52) were similar. No hypoglycaemic events were reported and no deaths occurred.

    INTERPRETATION: 6-week treatment with dapagliflozin did not affect proteinuria in patients with chronic kidney disease without diabetes, but did induce an acute and reversible decline in mGFR and a reduction in bodyweight. Long-term clinical trials are underway to determine whether SGLT2 inhibitors can safely reduce the rate of major clinical kidney outcomes in patients with chronic kidney disease with and without diabetes.

    FUNDING: AstraZeneca.

    Matched MeSH terms: Benzhydryl Compounds/adverse effects*
  4. EMPA-KIDNEY Collaborative Group
    Lancet Diabetes Endocrinol, 2024 Jan;12(1):51-60.
    PMID: 38061372 DOI: 10.1016/S2213-8587(23)00322-4
    BACKGROUND: The EMPA-KIDNEY trial showed that empagliflozin reduced the risk of the primary composite outcome of kidney disease progression or cardiovascular death in patients with chronic kidney disease mainly through slowing progression. We aimed to assess how effects of empagliflozin might differ by primary kidney disease across its broad population.

    METHODS: EMPA-KIDNEY, a randomised, controlled, phase 3 trial, was conducted at 241 centres in eight countries (Canada, China, Germany, Italy, Japan, Malaysia, the UK, and the USA). Patients were eligible if their estimated glomerular filtration rate (eGFR) was 20 to less than 45 mL/min per 1·73 m2, or 45 to less than 90 mL/min per 1·73 m2 with a urinary albumin-to-creatinine ratio (uACR) of 200 mg/g or higher at screening. They were randomly assigned (1:1) to 10 mg oral empagliflozin once daily or matching placebo. Effects on kidney disease progression (defined as a sustained ≥40% eGFR decline from randomisation, end-stage kidney disease, a sustained eGFR below 10 mL/min per 1·73 m2, or death from kidney failure) were assessed using prespecified Cox models, and eGFR slope analyses used shared parameter models. Subgroup comparisons were performed by including relevant interaction terms in models. EMPA-KIDNEY is registered with ClinicalTrials.gov, NCT03594110.

    FINDINGS: Between May 15, 2019, and April 16, 2021, 6609 participants were randomly assigned and followed up for a median of 2·0 years (IQR 1·5-2·4). Prespecified subgroupings by primary kidney disease included 2057 (31·1%) participants with diabetic kidney disease, 1669 (25·3%) with glomerular disease, 1445 (21·9%) with hypertensive or renovascular disease, and 1438 (21·8%) with other or unknown causes. Kidney disease progression occurred in 384 (11·6%) of 3304 patients in the empagliflozin group and 504 (15·2%) of 3305 patients in the placebo group (hazard ratio 0·71 [95% CI 0·62-0·81]), with no evidence that the relative effect size varied significantly by primary kidney disease (pheterogeneity=0·62). The between-group difference in chronic eGFR slopes (ie, from 2 months to final follow-up) was 1·37 mL/min per 1·73 m2 per year (95% CI 1·16-1·59), representing a 50% (42-58) reduction in the rate of chronic eGFR decline. This relative effect of empagliflozin on chronic eGFR slope was similar in analyses by different primary kidney diseases, including in explorations by type of glomerular disease and diabetes (p values for heterogeneity all >0·1).

    INTERPRETATION: In a broad range of patients with chronic kidney disease at risk of progression, including a wide range of non-diabetic causes of chronic kidney disease, empagliflozin reduced risk of kidney disease progression. Relative effect sizes were broadly similar irrespective of the cause of primary kidney disease, suggesting that SGLT2 inhibitors should be part of a standard of care to minimise risk of kidney failure in chronic kidney disease.

    FUNDING: Boehringer Ingelheim, Eli Lilly, and UK Medical Research Council.

    Matched MeSH terms: Benzhydryl Compounds/pharmacology; Benzhydryl Compounds/therapeutic use
  5. Santhi VA, Sakai N, Ahmad ED, Mustafa AM
    Sci Total Environ, 2012 Jun 15;427-428:332-8.
    PMID: 22578698 DOI: 10.1016/j.scitotenv.2012.04.041
    This study investigated the level of bisphenol A (BPA) in surface water used as potable water, drinking water (tap and bottled mineral water) and human plasma in the Langat River basin, Malaysia. BPA was present in 93% of the surface water samples at levels ranging from below limit of quantification (LOQ; 1.3 ng/L) to 215 ng/L while six fold higher levels were detected in samples collected near industrial and municipal sewage treatment plant outlets. Low levels of BPA were detected in most of the drinking water samples. BPA in tap water ranged from 3.5 to 59.8 ng/L with the highest levels detected in samples collected from taps connected to PVC pipes and water filter devices. Bottled mineral water had lower levels of BPA (3.3±2.6 ng/L) although samples stored in poor storage condition had significantly higher levels (11.3±5.3 ng/L). Meanwhile, only 17% of the plasma samples had detectable levels of BPA ranging from 0.81 to 3.65 ng/mL. The study shows that BPA is a ubiquitous contaminant in surface, tap and bottled mineral water. However, exposure to BPA from drinking water is very low and is less than 0.01% of the tolerable daily intake (TDI).
    Matched MeSH terms: Benzhydryl Compounds
  6. Jin M, Dang J, Paudel YN, Wang X, Wang B, Wang L, et al.
    Sci Total Environ, 2021 Jul 01;776:145963.
    PMID: 33639463 DOI: 10.1016/j.scitotenv.2021.145963
    Fluorene-9-bisphenol (BHPF) is a bisphenol A substitute, which has been introduced for the production of so-called 'bisphenol A (BPA)-free' plastics. However, it has been reported that BHPF can enter living organisms through using commercial plastic bottles and cause adverse effects. To date, the majority of the toxicologic study of BHPF focused on investigating its doses above the toxicological threshold. Here, we studied the effects of BHPF on development, locomotion, neuron differentiation of the central nervous system (CNS), and the expression of genes in the hypothalamic-pituitary-thyroid (HPT) axis in zebrafish exposed to different doses of BHPF ranging from 1/5 of LD1 to LD50 (300, 500, 750, 1500, 3000, and 4500 nM). As a result, the possible hormetic effects of BHPF on regulating the HPT axis were revealed, in which low-dose BHPF positively affected the HPT axis while this regulation was inhibited as the dose increased. Underlying mechanism investigation suggested that BHPF disrupted myelination through affecting HPT axis including related genes expression and TH levels, thus causing neurotoxic characteristics. Collectively, this study provides the full understanding of the environmental impact of BHPF and its toxicity on living organisms, highlighting a substantial and generalized ongoing dose-response relationship with great implications for the usage and risk assessment of BHPF.
    Matched MeSH terms: Benzhydryl Compounds
  7. The EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, et al.
    N Engl J Med, 2023 Jan 12;388(2):117-127.
    PMID: 36331190 DOI: 10.1056/NEJMoa2204233
    BACKGROUND: The effects of empagliflozin in patients with chronic kidney disease who are at risk for disease progression are not well understood. The EMPA-KIDNEY trial was designed to assess the effects of treatment with empagliflozin in a broad range of such patients.

    METHODS: We enrolled patients with chronic kidney disease who had an estimated glomerular filtration rate (eGFR) of at least 20 but less than 45 ml per minute per 1.73 m2 of body-surface area, or who had an eGFR of at least 45 but less than 90 ml per minute per 1.73 m2 with a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of at least 200. Patients were randomly assigned to receive empagliflozin (10 mg once daily) or matching placebo. The primary outcome was a composite of progression of kidney disease (defined as end-stage kidney disease, a sustained decrease in eGFR to <10 ml per minute per 1.73 m2, a sustained decrease in eGFR of ≥40% from baseline, or death from renal causes) or death from cardiovascular causes.

    RESULTS: A total of 6609 patients underwent randomization. During a median of 2.0 years of follow-up, progression of kidney disease or death from cardiovascular causes occurred in 432 of 3304 patients (13.1%) in the empagliflozin group and in 558 of 3305 patients (16.9%) in the placebo group (hazard ratio, 0.72; 95% confidence interval [CI], 0.64 to 0.82; P<0.001). Results were consistent among patients with or without diabetes and across subgroups defined according to eGFR ranges. The rate of hospitalization from any cause was lower in the empagliflozin group than in the placebo group (hazard ratio, 0.86; 95% CI, 0.78 to 0.95; P = 0.003), but there were no significant between-group differences with respect to the composite outcome of hospitalization for heart failure or death from cardiovascular causes (which occurred in 4.0% in the empagliflozin group and 4.6% in the placebo group) or death from any cause (in 4.5% and 5.1%, respectively). The rates of serious adverse events were similar in the two groups.

    CONCLUSIONS: Among a wide range of patients with chronic kidney disease who were at risk for disease progression, empagliflozin therapy led to a lower risk of progression of kidney disease or death from cardiovascular causes than placebo. (Funded by Boehringer Ingelheim and others; EMPA-KIDNEY ClinicalTrials.gov number, NCT03594110; EudraCT number, 2017-002971-24.).

    Matched MeSH terms: Benzhydryl Compounds/adverse effects; Benzhydryl Compounds/therapeutic use
  8. Tan BL, Ali Mohd M
    Talanta, 2003 Nov 4;61(3):385-91.
    PMID: 18969198 DOI: 10.1016/S0039-9140(03)00281-9
    A total of seven pesticides and eight alkylphenols were monitored using this method for the determination of their trace levels in human cord blood. The pesticides are lindane, diazinon, alpha-endosulfan, beta-endosulfan, endosulfan sulfate, chlorpyrifos and endrin; while the alkylphenols are 4-n-butylphenol, 4-n-pentylphenol, 4-n-hexylphenol, 4-t-octylphenol, 4-n-heptylphenol, nonylphenol, 4-n-octylphenol and bisphenol A. The pesticides and alkylphenols in the cord blood samples were extracted with solid phase extraction IST C18 cartridges and analyzed by selected ion monitoring mode using quadrapole detector in Shimadzu QP-5000 gas chromatograph-mass spectrometer. Trace levels of pesticide and alkylphenols in the range of non-detectable to 15.17 ng ml(-1), were detected in the human cord blood samples. This technique of monitoring the levels of endocrine-disruptors in blood samples is consistent, reliable and cost effective while reducing wastage of time and solvents.
    Matched MeSH terms: Benzhydryl Compounds
  9. Rozaini MNH, Yahaya N, Saad B, Kamaruzaman S, Hanapi NSM
    Talanta, 2017 Aug 15;171:242-249.
    PMID: 28551135 DOI: 10.1016/j.talanta.2017.05.006
    Molecularly imprinted polymer (MIP) was employed as sorbent in ultrasound assisted emulsification molecularly imprinted polymer micro-solid phase extraction (USAE-MIP-µ-SPE) of bisphenol A (BPA) in water, beverages and the aqueous liquid in canned foods prior to high performance liquid chromatography-diode array detector (HPLC-DAD) analysis. Several effective variables, such as types of emulsification solvent and its volume, types of desorption solvent and its volume, salting out effect, pH of sample solution, mass of sorbent, extraction and desorption time, and sample volume, were optimized comprehensively. Under the optimized USAE-MIP-µ-SPE and HPLC-DAD conditions, the method demonstrated good linearity over the range of 0.5-700μgL-1with a coefficient determination of R2=0.9973, low limit of detection (0.07μgL-1), good analyte recoveries (82.2-118.9%) and acceptable RSDs (0.7-14.2%, n=3) with enrichment factor of 49. The method was applied to thirty samples of drinking water, mineral water, river water, lake water, as well as beverages and canned foods, the presence of BPA was identified in four samples. The proposed method showed good selectivity and reusability for extraction of BPA, and hence the USAE-MIP-µ-SPE is rapid, simple, cost effective and environmentally friendly.
    Matched MeSH terms: Benzhydryl Compounds
  10. Zainul R, Abd Azis N, Md Isa I, Hashim N, Ahmad MS, Saidin MI, et al.
    Sensors (Basel), 2019 Feb 22;19(4).
    PMID: 30813385 DOI: 10.3390/s19040941
    This paper presents the application of zinc/aluminium-layered double hydroxide-quinclorac (Zn/Al-LDH-QC) as a modifier of multiwalled carbon nanotubes (MWCNT) paste electrode for the determination of bisphenol A (BPA). The Zn/Al-LDH-QC/MWCNT morphology was examined by a transmission electron microscope and a scanning electron microscope. Electrochemical impedance spectroscopy was utilized to investigate the electrode interfacial properties. The electrochemical responses of the modified electrode towards BPA were thoroughly evaluated by using square-wave voltammetry technique. The electrode demonstrated three linear plots of BPA concentrations from 3.0 × 10-8⁻7.0 × 10-7 M (R² = 0.9876), 1.0 × 10-6⁻1.0 × 10-5 M (R² = 0.9836) and 3.0 × 10-5⁻3.0 × 10-4 M (R² = 0.9827) with a limit of detection of 4.4 × 10-9 M. The electrode also demonstrated good reproducibility and stability up to one month. The presence of several metal ions and organic did not affect the electrochemical response of BPA. The electrode is also applicable for BPA determination in baby bottle and mineral water samples with a range of recovery between 98.22% and 101.02%.
    Matched MeSH terms: Benzhydryl Compounds
  11. Shehab ZN, Jamil NR, Aris AZ
    Sci Rep, 2020 11 23;10(1):20360.
    PMID: 33230250 DOI: 10.1038/s41598-020-77454-8
    Phase distribution of emerging organic contaminants is highly influential in their presence, fate and transport in surface water. Therefore, it is crucial to determine their state, partitioning behaviour and tendencies in water environments. In this study, Bisphenol A was investigated in both colloidal and soluble phases in water. BPA concentrations ranged between 1.13 and 5.52 ng L-1 in the soluble phase and n.d-2.06 ng L-1 in the colloidal phase, respectively. BPA was dominant in the soluble phase, however, the colloidal contribution ranged between 0 and 24% which implied that colloids can play a significant role in controlling BPA's transportation in water. Urban and industrial areas were the main sources of BPA while forest areas displayed lower levels outside the populated domains. pH levels were between 6.3 and 7.4 which might have affected BPA's solubility in water to some extent. The particle size distribution showed that the majority of the particles in river samples were smaller than 1.8 µm in diameter with a small presence of nanoparticles. Zeta potential varied between - 25 and - 18 mV, and these negative values suggested instability of particles. Furthermore, BPA was positively correlated with BOD, COD and NH3-N which might indicate that these organic compounds were released concurrently with BPA. RQ assessment showed low levels of risk towards algae and fish in the study area.
    Matched MeSH terms: Benzhydryl Compounds
  12. Wee SY, Aris AZ, Yusoff FM, Praveena SM
    Sci Rep, 2020 10 20;10(1):17755.
    PMID: 33082440 DOI: 10.1038/s41598-020-74061-5
    Contamination by endocrine disrupting compounds (EDCs) concerns the security and sustainability of a drinking water supply system and human exposure via water consumption. This study analyzed the selected EDCs in source (river water, n = 10) and supply (tap water, n = 155) points and the associated risks. A total of 14 multiclass EDCs was detected in the drinking water supply system in Malaysia. Triclosan (an antimicrobial agent) and 4-octylphenol (a plasticizer) were only detected in the tap water (up to 9.74 and 0.44 ng/L, respectively). Meanwhile, chloramphenicol and 4-nonylphenol in the system were below the method detection limits. Bisphenol A was observed to be highest in tap water at 66.40 ng/L (detection: 100%; median concentration: 0.28 ng/L). There was a significant difference in triclosan contamination between the river and tap water (p 
    Matched MeSH terms: Benzhydryl Compounds/analysis
  13. Rasdi Z, Kamaludin R, Ab Rahim S, Syed Ahmad Fuad SB, Othman MHD, Siran R, et al.
    Sci Rep, 2020 Apr 03;10(1):5882.
    PMID: 32246001 DOI: 10.1038/s41598-020-62420-1
    This study aimed to examine the impact of BPA exposure on pregnancy and foetuses on cardiac tissues and the expression of cardiac microRNAs (miRNAs) related to heart development and diseases. Pregnancy is known to be the "critical windows" in determining the offspring physical and cells development in their life after birth. The increment of the risk of cardiovascular disease (CVD) in a later stage of life has been reported by few studies demonstrated from prenatal exposure of BPA. BPA has been shown to alter miRNAs expression profiles for organ development, regeneration and metabolic functions. These alterations have been associated with the risk of CVDs. However, the associations between pregnancy outcomes and miRNAs expression in cardiac of mother- and foetuses-exposed to BPA are still not entirely explored. In BPA-exposed pregnant rat groups, a significant weight gained was observed in comparison to control (p 
    Matched MeSH terms: Benzhydryl Compounds/adverse effects*
  14. Shan TO, Mee LN, Marinah Mohd Ariffin, Saw HL
    Sains Malaysiana, 2017;46:615-621.
    Bisphenol A is an endocrine disruptor with widespread applications, especially in the production of polycarbonate and epoxy resins. Dispersive liquid-liquid microextraction based on solidification of floating organic technique has been developed for the extraction of bisphenol A from water and soft drink. The 1-undecanol has been applied as the extraction solvent because of its low density and melting point and high affinity to the analyte. The technique offered rapid and simple analysis as the 1-undecanol was homogeneously dispersed in the sample solution to speed the extraction and the collection of extraction solvent was simplified by centrifugation, cooling and melting steps.
    Matched MeSH terms: Benzhydryl Compounds
  15. Dzuhri S, Yuhana N, Khairulazfar M
    Sains Malaysiana, 2015;44:441-448.
    This study utilized the incorporation of nanoparticle filler into an epoxy system to study the effect of different nanosized
    montmorillonite (MMT) fillers on the thermal stability and mechanical properties of epoxy. The sample was prepared
    using diglycidyl ether of bisphenol A (DGEBA) with different surface treatments of montmorillonite filler by mechanical
    stirring. The results of thermal stability and mechanical properties of epoxy/clay system obtained from thermal gravimetric
    analyzer (TGA), universal testing machine (UTM) and scanning electron microscopy (SEM) were discussed. With the same
    amount of filler introduced into the system, different thermal stability of epoxy composite can be observed. Bentonite,
    which contained other contaminant components, can downgrade the enhanced properties of the filler.
    Matched MeSH terms: Benzhydryl Compounds
  16. Hassan R, Aslam Khan MU, Abdullah AM, Abd Razak SI
    Polymers (Basel), 2021 Apr 27;13(9).
    PMID: 33925332 DOI: 10.3390/polym13091409
    Polymeric materials have always established an edge over other classes of materials due to their potential applications in various fields of biomedical engineering. Orthodontics is an emerging field in which polymers have attracted the enormous attention of researchers. In particular, thermoplastic materials have a great future utility in orthodontics, both as aligners and as retainer appliances. In recent years, the use of polycarbonate brackets and base monomers bisphenol A glycerolate dimethacrylate (bis-GMA) has been associated with the potential release of bisphenol A (BPA) in the oral environment. BPA is a toxic compound that acts as an endocrine disruptor that can affect human health. Therefore, there is a continuous search for non-BPA materials with satisfactory mechanical properties and an esthetic appearance as an alternative to polycarbonate brackets and conventional bis-GMA compounds. This study aims to review the recent developments of BPA-free monomers in the application of resin dental composites and adhesives. The most promising polymeric smart materials are also discussed for their relevance to future orthodontic applications.
    Matched MeSH terms: Benzhydryl Compounds
  17. Mohamed AD, Lewis CR
    PLoS One, 2014;9(11):e110639.
    PMID: 25391155 DOI: 10.1371/journal.pone.0110639
    BACKGROUND: Modafinil is a medication licensed for the treatment of narcolepsy. However, it has been reported that healthy individuals without wakefulness disorders are using modafinil off-label to enhance cognitive functioning. Although some studies have reported that modafinil improves cognitive task performance in healthy volunteers, numerous other studies have failed to detect cognitive enhancing effects of modafinil on several well-established neuropsychological tasks. Interestingly, several clinical and preclinical studies have found that improved cognitive task performance by modafinil is accompanied by slower response times. This observation raises the question as to whether this slowing of response time in healthy volunteers is a necessary and sufficient condition for cognitive enhancement with modafinil. The aim of the current experiment was to explore this question by investigating the effects of modafinil on the Hayling Sentence Completion Test (HSCT).

    METHODOLOGY: Sixty-four healthy volunteers received either a single dose (200 mg) of modafinil (n = 32) or placebo (n = 32) in a randomized, double-blind, placebo-controlled, parallel group study in which the principal outcome measures were response latencies on the response initiation and response inhibition sections of the HSCT.

    PRINCIPAL FINDINGS: Participants dosed with modafinil had significantly longer mean response latencies on the HSCT for both the response initiation and response inhibition compared to participants dosed with placebo. However, participants in both groups made a similar number of errors on each of these measures, indicating that modafinil did not enhance the accuracy of performance of the task relative to placebo.

    CONCLUSIONS: This study demonstrated that administration of single 200 mg doses of modafinil to healthy individuals increased the latency of responses in the performance of the HSCT, a task that is highly sensitive to prefrontal executive function, without enhancing accuracy of performance. This finding may provide important clues to defining the limitations of modafinil as a putative cognitive enhancer.

    TRIAL REGISTRATION: ClinicalTrials.gov NCT02051153.

    Matched MeSH terms: Benzhydryl Compounds/chemistry*
  18. Qattan MY, Bakker EY, Rajendran R, Chen DW, Saha V, Liu J, et al.
    PLoS One, 2017;12(6):e0178606.
    PMID: 28582465 DOI: 10.1371/journal.pone.0178606
    Glucocorticoids (GCs) and topoisomerase II inhibitors are used to treat acute lymphoblastic leukaemia (ALL) as they induce death in lymphoid cells through the glucocorticoid receptor (GR) and p53 respectively. Mechanisms underlying ALL cell death and the contribution of the bone marrow microenvironment to drug response/resistance remain unclear. The role of the microenvironment and the identification of chemoresistance determinants were studied by transcriptomic analysis in ALL cells treated with Dexamethasone (Dex), and Etoposide (Etop) grown in the presence or absence of bone marrow conditioned media (CM). The necroptotic (RIPK1) and the apoptotic (caspase-8/3) markers were downregulated by CM, whereas the inhibitory effects of chemotherapy on the autophagy marker Beclin-1 (BECN1) were reduced suggesting CM exerts cytoprotective effects. GCs upregulated the RIPK1 ubiquitinating factor BIRC3 (cIAP2), in GC-sensitive (CEM-C7-14) but not in resistant (CEM-C1-15) cells. In addition, CM selectively affected GR phosphorylation in a site and cell-specific manner. GR is recruited to RIPK1, BECN1 and BIRC3 promoters in the sensitive but not in the resistant cells with phosphorylated GR forms being generally less recruited in the presence of hormone. FACS analysis and caspase-8 assays demonstrated that CM promoted a pro-survival trend. High molecular weight proteins reacting with the RIPK1 antibody were modified upon incubation with the BIRC3 inhibitor AT406 in CEM-C7-14 cells suggesting that they represent ubiquitinated forms of RIPK1. Our data suggest that there is a correlation between microenvironment-induced ALL proliferation and altered response to chemotherapy.
    Matched MeSH terms: Benzhydryl Compounds/pharmacology
  19. Balakumar P, Sundram K, Dhanaraj SA
    Pharmacol Res, 2014 Apr;82:34-9.
    PMID: 24705156 DOI: 10.1016/j.phrs.2014.03.008
    Diabetes mellitus is a greatly challenging disease of the 21 century, and the mortality rate due to this insidious disease is increasing worldwide in spite of availability of effective oral hypoglycemic agents. Satisfactory management of glycemic control in patients afflicted with type 2 diabetes mellitus (T2DM) remains a major clinical challenge. Identification of potential pharmacological target sites is therefore continuing as an integral part of the diabetic research. The sodium-glucose co-transporter type 2 (SGLT2) expressed in the renal proximal tubule plays an essential role in glucose reabsorption. Pharmacological blockade of SGLT2 prevents glucose reabsorption and subsequently induces the elimination of filtered glucose via urine, the process is known as 'glucuresis'. Dapagliflozin is a selective inhibitor of SGLT2. The US FDA approved dapagliflozin in January 2014 to improve glycemic control along with diet and exercise in adult patients afflicted with T2DM. It has a potential to decrease glycated hemoglobin and to promote weight loss. Although the mechanism of action of dapagliflozin is not directly linked with insulin or insulin sensitivity, reduction of plasma glucose by dapagliflozin via induction of glucosuria could improve muscle insulin sensitivity. Moreover, dapagliflozin could cause diuresis and subsequently fall in blood pressure. In addition to general discussion on the pharmacology of dapagliflozin, we propose in this review the possibilities of dual antidiabetic effect of dapagliflozin and its possible additional beneficial actions in hypertensive-obese-T2DM patients through its indirect blood pressure-lowering action and reduction of body calories and weight. Long-term clinical studies are however needed to clarify this contention.
    Matched MeSH terms: Benzhydryl Compounds/adverse effects; Benzhydryl Compounds/pharmacokinetics; Benzhydryl Compounds/pharmacology*; Benzhydryl Compounds/therapeutic use
  20. M Hanif A, Bushra R, Ismail NE, Bano R, Abedin S, Alam S, et al.
    Pak J Pharm Sci, 2021 May;34(3(Supplementary)):1081-1087.
    PMID: 34602436
    The current investigation is based on efficient method development for the quantification of empagliflozin in raw and pharmaceutical dosage forms, as no pharmacopoeial method for the drug is available so far. The developed analytical method was validated as per ICH guidelines. C18 column with mobile phase (pH 4.8) consisted of 0.1% trifluoroacetic acid solution and acetonitrile (70:30 v/v) was used for drug analysis. The calibration plot showed good linear regression (r2>0.999) over the concentration of 0.025-30 μg mL-1. The LOD and LOQ were found to be 0.020 μg mL-1 and 0.061 μg mL-1, respectively. The percentage recovery was estimated between 98.0 to 100.13%. Accuracy and precision data were found to be less than 2%, indicating the suitability of method for routine analysis in pharmaceutical industries. Moreover, the drug solution was found to be stable in refrigerator and ambient room temperature with mean % accuracy of >98%. Empagliflozin contents were also tested in both the raw API and marketed tablet brands using this newly developed method. The mean assay of raw empagliflozin and tablet brands were ranged from 99.29%±1.12 to 100.95%±1.69 and 97.18%±1.59 to 98.92%±1.00 respectively. Based on these findings, the present investigated approach is suitable for quantification of empagliflozin in raw and pharmaceutical dosage forms.
    Matched MeSH terms: Benzhydryl Compounds/analysis*
Filters
Contact Us

Please provide feedback to Administrator (afdal@afpm.org.my)

External Links